Shots:

• Idorsia to receive $45M upfront in cash- $365M for development & regulatory milestone- one-time sales threshold and royalties on sales. Additionally- will receive $7M in funding to discover- identify and develop additional novel T-type calcium channel blockers
• Neurocrine exercises its option to license rights for ACT-709478 (post IND acceptance from the US FDA on Apr 30- 2020) for rare pediatric epilepsy. In 2019- Neurocrine and Idorsia signed a preclinical research collaboraion for ACT-709478 to treat rare pediatric epilepsy
• ACT-709478 is an selective- orally-active and brain penetrating T-type calcium channel blocker also received the US FDA's Rare Pediatric Disease designation for rare pediatric epilepsy with completion of P-I in 2019 and expected P-II initiation in in H2'20

Click here to read full press release/ article | Ref: GlobeNewswire | Image:Twitter